{"id":15110,"date":"2019-10-18T14:29:24","date_gmt":"2019-10-18T14:29:24","guid":{"rendered":"https:\/\/www.upjs.sk\/pracoviska\/tip\/ctm\/focus-of-research\/"},"modified":"2023-06-28T09:00:36","modified_gmt":"2023-06-28T09:00:36","slug":"focus-of-research","status":"publish","type":"page","link":"https:\/\/www.upjs.sk\/pracoviska\/tip\/en\/our-centers\/ctm\/focus-of-research\/","title":{"rendered":"Focus of research"},"content":{"rendered":"\n

<\/a>Personalized medicine<\/mark><\/strong>
Although today’s diagnostic is based on modern trends in genomics, proteomics, metabolomics, bioinformatics, molecular and cell biology methods, many oncology patients are still dying due to late, incorrect or inaccurate diagnostics. According to america\u2018s nationwide survey of 400 prestigious oncology specialists, the rate of incorrect and inaccurate diagnostics is 28%, with some types of cancer even more than 50% (e.g. breast cancer, lymphatic vessels cancer, sarcomas). The main causes are the absence of biomarker, incorrect cancer characteristics, incorrect pathology of the tissue due to limiting diagnostic technologies, inadequate genetic and genomic information available at the time of diagnosis. However, the biggest problem of today’s cancer diagnostics is that the specific biomarker can not be accurately quantified and thus the therapy is not set up correctly and eventually becomes inaccurate and unsuccessful.<\/p>\n\n\n\n

    \n
  1. Personalized diagnostics
    The first objective of the personalized medicine program is therefore to develop early, accurate, specific, quantifiable, multiplexed, readily available and inexpensive diagnostic tests that would help to effectively and successfully treat and prevent cancer. The principle will be the quantification (visualization and sequencing) of all 3 basic biomarkers (DNA, RNA and protein) as well as their simultaneous visualization. CTM will be based on the development of new and modern diagnostic biotechnology methods by linking nucleic acid chemistry, biochemistry, genomics, proteomics, bioinformatics, molecular biology, pathology and medicine with using high resolution microscopy and 3D visualization of biopsies of single cell or microscopic genome in the cell nucleus, and also by new sequencing technologies, and other methods including qPCR, DNA microarray, FACS, Elisa.<\/li>\n\n\n\n
  2. Personalized therapy
    The second objective of the personalized medicine program is to develop modern oncology treatments based on outputs from pharmacogenetics and pharmacogenomics, development of gene and viral therapies (including the development of new generations of iRNA drugs and CRISPR \/ Cas9 of modern gene therapy), new radiation therapies, discovery of new drugs including phenotyp screening, application of new drugs (including nanotechnologies).<\/li>\n<\/ol>\n\n\n